AOD-9604: Research on the Growth Hormone Fragment Peptide

Compiled by the APL Research TeamSourced directly from peer-reviewed pharmacological literature and clinical guidelines.

Key Takeaways

• Expert Insight: An overview of AOD-9604, a modified fragment of human growth hormone (hGH 176-191), covering its mechanism of action in lipolysis research, metabolic studies, and cartilage repair models.
• Quality Assurance: All discussed methodologies align with stringent Australian laboratory standards.
• Clinical Relevance: Critical informational resource for verifying the stability and purity of aod-9604: research on the growth hormone fragment peptide in-vitro.

Introduction

AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to the C-terminal fragment of human growth hormone (hGH), specifically amino acids 176-191, with a tyrosine modification at position 182. Developed at Monash University in Melbourne, Australia, AOD-9604 was designed to isolate the lipolytic (fat-metabolising) activity of growth hormone from its growth-promoting and diabetogenic effects.

The rationale behind AOD-9604 is that different regions of the GH molecule mediate different biological functions. The C-terminal region (176-191) had been identified as important for GH's effects on lipid metabolism, while the N-terminal region is primarily responsible for growth promotion and IGF-1 stimulation.

Molecular Profile

Mechanism of Action

Lipolytic Pathway

AOD-9604's primary researched mechanism involves stimulation of lipolysis through a pathway distinct from GH receptor signalling:

• Beta-3 adrenergic receptor interaction — research suggests AOD-9604 may enhance lipolysis via beta-3 adrenergic receptor-mediated pathways in adipose tissue
• Hormone-sensitive lipase (HSL) activation — the peptide appears to increase HSL activity, the rate-limiting enzyme in triglyceride hydrolysis
• Inhibition of lipogenesis — in addition to promoting fat breakdown, AOD-9604 has been reported to inhibit the formation of new fatty acids (de novo lipogenesis) in animal models
• No IGF-1 stimulation — unlike full-length GH, AOD-9604 does not increase IGF-1 levels at lipolytic doses, confirming the functional separation of GH's metabolic and growth-promoting activities

Distinction from Full-Length GH

The key research value of AOD-9604 lies in what it does not do:

This selectivity makes AOD-9604 a valuable research tool for studying the metabolic effects of GH signalling in isolation from its anabolic and potentially diabetogenic effects.

Key Research Findings

Adipose Tissue Studies

The foundational research on AOD-9604 was conducted at Monash University:

• In-vitro studies using human adipose tissue explants demonstrated dose-dependent stimulation of lipolysis
• The lipolytic effect was comparable to full-length GH on a molar basis
• Chronic treatment in obese Zucker rats reduced body weight gain without affecting food intake, lean body mass, or IGF-1 levels
• Fat pad mass was reduced in treated animals, with preferential reduction of visceral adipose tissue

Metabolic Studies

Animal studies examined broader metabolic effects:

• No effect on fasting glucose or insulin levels, suggesting no diabetogenic activity
• Improved lipid profiles in diet-induced obesity models (reduced triglycerides, reduced LDL cholesterol)
• No effect on appetite or food intake — weight reduction was attributed to increased energy expenditure and lipolysis, not caloric restriction
• No tachyphylaxis observed over chronic dosing periods in animal studies

Cartilage and Joint Research

An unexpected area of AOD-9604 research emerged in the context of cartilage biology:

• Stimulation of proteoglycan and collagen synthesis in cultured chondrocytes
• Enhanced cartilage repair in animal models of joint injury
• Promotion of mesenchymal stem cell differentiation toward chondrogenic lineage
• These findings were investigated by Australian researchers and led to clinical-stage cartilage repair studies

Bone Metabolism

Preliminary research has examined AOD-9604's effects on bone:

• Stimulation of osteoblast proliferation in cell culture models
• Increased bone mineral content in ovariectomised rat models
• The mechanism may relate to GH fragment effects on mesenchymal stem cell differentiation, which can be directed toward both chondrogenic and osteogenic lineages

Pharmacological Profile

Oral Bioavailability

One notable characteristic of AOD-9604 in preclinical research was its reported oral bioavailability — unusual for a peptide of its size:

• Oral administration in animal models produced measurable plasma levels and biological effects
• The mechanism of oral absorption is not fully elucidated but may involve paracellular transport across the intestinal epithelium
• Oral bioavailability was sufficient for pharmacological effects in some studies, though injectable routes produced more consistent pharmacokinetics

Stability

• AOD-9604 is relatively stable compared to many peptides, attributed to its sequence composition and the protective Tyr¹⁸² modification
• The disulfide bond between Cys¹⁸² and Cys¹⁸⁹ in the native GH sequence is absent in AOD-9604, simplifying handling
• Standard reconstitution and storage protocols apply — see our Reconstitution Best Practices guide

Australian Research Context

AOD-9604 has particular significance in the Australian research peptide landscape:

• Developed by Professor Frank Ng at Monash University, Melbourne
• Research was conducted in collaboration with Metabolic Pharmaceuticals Ltd (ASX-listed)
• The peptide represents a notable example of Australian contributions to peptide therapeutics research
• Received GRAS (Generally Recognized as Safe) status from the U.S. FDA in 2010 for use as a food additive

Research Considerations

AOD-9604 is supplied as a lyophilised white powder. Reconstitute with bacteriostatic water following standard protocols. For detailed handling instructions, see our guides on Reconstitution Best Practices and Peptide Storage and Stability.

When designing experiments with AOD-9604, consider:

• The distinction between lipolytic and growth-promoting GH activities — use full-length GH or GH-releasing peptides as positive controls for IGF-1-mediated effects
• Dose-response relationships may differ between in-vitro and in-vivo models
• The route of administration affects pharmacokinetics — injectable routes provide more consistent systemic exposure than oral administration

All research involving AOD-9604 should be conducted in accordance with institutional protocols. This compound is designated for laboratory research use only.

Frequently Asked Questions

Is AOD-9604 legal to buy and research in Australia? AOD-9604 is supplied strictly as a research chemical for in-vitro laboratory use. It is not approved for human therapeutic use in Australia and is not for human or animal consumption. Researchers are responsible for compliance with Therapeutic Goods Administration (TGA) regulations and their institution's protocols.

What is AOD-9604 and what is it studied for? AOD-9604 is a synthetic fragment of human growth hormone (hGH 176-191), originally developed in Australia, designed to isolate GH's lipolytic (fat-metabolising) activity from its growth-promoting effects. In preclinical research it has been studied for lipolysis, metabolic endpoints in obesity models, and cartilage and bone repair — notably without elevating IGF-1. These are laboratory findings only and do not establish any effect in humans.

How is the purity of AOD-9604 verified? Every batch is analysed in-house by HPLC and mass spectrometry and ships with a Certificate of Analysis. Select batches also undergo independent, third-party purity verification.

How should AOD-9604 be stored and reconstituted? AOD-9604 ships as a lyophilised white powder and is relatively stable for a peptide of its size. Store the lyophilised powder at -20°C, reconstitute with bacteriostatic water following standard protocols, and keep the reconstituted solution at 2-8°C, protected from light.

Does Australian Peptide Labs provide AOD-9604 dosing protocols? No. As these compounds are supplied for laboratory research only, we do not provide dosing or administration protocols. Our research library covers reconstitution and concentration calculations for in-vitro work.

References

1. Ng, F.M. et al. "Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone." Hormone Research, 2000. — PubMed: 11146367
2. Heffernan, M. et al. "The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice." Endocrinology, 2001. — PubMed: 11713213
3. Kwon, D.R. et al. "Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model." Annals of Clinical and Laboratory Science, 2015. — PubMed: 26275694

⚠️ Medical & Regulatory Disclaimer:
The information provided in this academic article is intended exclusively for educational and laboratory research purposes. It does NOT constitute medical advice. Compounds discussed are strictly for in-vitro research and development only, and are not intended for human consumption, veterinary use, or clinical treatment. Always adhere to Australian Therapeutic Goods Administration (TGA) regulations and your institution's ethical guidelines when handling research chemicals.